Is this the age of the big biotech buyout? Is cold brew a business expense? And how do you pronounce “Gonzalez”?

We discuss all that and more on the latest episode of “The Readout LOUD,” STAT’s biotech podcast. First, STAT’s Matt Herper joins us to break down the Senate Finance Committee hearing that saw seven pharmaceutical executives taken to task on the topic of drug pricing. Then, Matt sticks around to talk about what a spate of billion-dollar deals mean for the future of biotech. Later, STAT reporter Kate Sheridan stops by to talk about what you can — and can’t — learn about stealthy biotech startups when you do a little digging. Finally, we embark upon a lightning round that touches on Bristol-Myers Squibb’s increasingly difficult quest to buy Celgene, a controversial effort toward gender parity, and some unwanted brand recognition for Novartis.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy